Mesotelioma pleural maligno

Abstract

Malignant pleural mesothelioma is a neoplasm with high mortality of 99% at 5 years and with little prospect of treatment, facing different problems such as the rarity of the disease, the difficulty of staging, aggressive nature, little sensitivity to this combined chemotherapy aggressive surgical procedures that few patients can tolerate because of their age and suffer various diseases coomorbidas. The surgical procedures used are extrapleral pleurotomy and more pleurotomy pleurodesis decortication and yet all these procedures are palliative only limited control and high rates of recurrence as a single treatment. Has been offered other treatments such as conventional chemotherapy having little benefit with platinum-based schemes more pemetrexed giving a benefit of 3 months compared with platinum alone have survivals of four to 12 months. Attempts have been combining chemotherapy with other therapies such as anti angiogenic inhibitors tirosinkinasa, the use of immunosuppressants which have shown no benefit or is able to overcome the combination of pemetrexed with platinum.